These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19631839)

  • 41. Cross-country comparisons of costs: the use of episode-specific transitive purchasing power parities with standardised cost categories.
    Schreyögg J; Tiemann O; Stargardt T; Busse R
    Health Econ; 2008 Jan; 17(1 Suppl):S95-103. PubMed ID: 18186031
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
    Kumar A; Fonarow GC; Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Boden WE; Steg PG; Shao M; Bhatt DL; Cannon CP;
    Crit Pathw Cardiol; 2009 Sep; 8(3):104-11. PubMed ID: 19726929
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
    Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
    Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of flare on disease costs of patients with systemic lupus erythematosus.
    Zhu TY; Tam LS; Lee VW; Lee KK; Li EK
    Arthritis Rheum; 2009 Sep; 61(9):1159-67. PubMed ID: 19714597
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.
    Teo KK; Sedlis SP; Boden WE; O'Rourke RA; Maron DJ; Hartigan PM; Dada M; Gupta V; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
    J Am Coll Cardiol; 2009 Sep; 54(14):1303-8. PubMed ID: 19778673
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Depression: a social mortgage. Latest advances in knowledge of the cost of the disease].
    Valladares A; Dilla T; Sacristán JA
    Actas Esp Psiquiatr; 2009; 37(1):49-53. PubMed ID: 18781410
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The economics of enteric infections: human foodborne disease costs.
    Buzby JC; Roberts T
    Gastroenterology; 2009 May; 136(6):1851-62. PubMed ID: 19457414
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increase in lipid-lowering treatment rates among TRICARE beneficiaries: a population-based study.
    Devine J; Linton A; Mistry H; Napier J; Trice S; Bacon T
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):891-9. PubMed ID: 19634117
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lessons from the REACH Registry in Europe.
    Valentijn TM; Stolker RJ
    Curr Vasc Pharmacol; 2012 Nov; 10(6):725-7. PubMed ID: 23259566
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Atherothrombosis: an excessively globalizing concept?].
    Castillo J; Blanco M
    Med Clin (Barc); 2009 Sep; 132 Suppl 2():2-4. PubMed ID: 19631830
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes.
    Baker WL; White CM
    Am J Cardiovasc Drugs; 2009; 9(4):213-29. PubMed ID: 19655817
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification and management of polyvascular disease in patients with noncardioembolic ischaemic stroke.
    Carolei A; Chamorro A; Laloux P; Leys D; Röther J; Sander D; Stansby G; Weimar C
    Int J Stroke; 2008 Nov; 3(4):237-48. PubMed ID: 18811739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sirolimus-eluting stent treatment at high-volume centers confers lower mortality at 6-month follow-up: results from the prospective multicenter German Cypher Registry.
    Khattab AA; Hamm CW; Senges J; Toelg R; Geist V; Bonzel T; Kelm M; Levenson B; Nienaber CA; Pfannebecker T; Sabin G; Schneider S; Tebbe U; Neumann FJ; Richardt G;
    Circulation; 2009 Aug; 120(7):600-6. PubMed ID: 19652087
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic impact of types of atrial fibrillation in acute coronary syndromes.
    Lau DH; Huynh LT; Chew DP; Astley CM; Soman A; Sanders P
    Am J Cardiol; 2009 Nov; 104(10):1317-23. PubMed ID: 19892044
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Farm-level economic analysis of the US National Johne's Disease Demonstration Herd Project.
    Groenendaal H; Wolf CA
    J Am Vet Med Assoc; 2008 Dec; 233(12):1852-8. PubMed ID: 19072597
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Future pharmacoeconomic criteria for the treatment of infections.
    Milkovich G
    Int J Antimicrob Agents; 2009 Jul; 34 Suppl 1():S12-4. PubMed ID: 19560668
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The economic characteristics of registries and their policy implications.
    Connelly LB
    J Trauma; 2009 Feb; 66(2):531-5. PubMed ID: 19204534
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Where on the healthcare continuum should we invest? The case for primary care?
    Tonkin AM; Chen L
    Heart Lung Circ; 2009 Apr; 18(2):108-13. PubMed ID: 19119071
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Economic cost analysis in cancer management and its relevance today.
    Sharma K; Das S; Mukhopadhyay A; Rath GK; Mohanti BK
    Indian J Cancer; 2009; 46(3):184-9. PubMed ID: 19574668
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Statines for all or individualized lipid lowering therapy?].
    Parhofer K
    MMW Fortschr Med; 2009 Apr; 151(14):100, 102-4; quiz 105. PubMed ID: 19504849
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.